INTENT Biologics is dedicated to developing innovative, first-in-class exosome-based therapeutics designed to transform the treatment landscape for standards of care in inflammation and immunology.
THE SCIENCE

INTENT’s groundbreaking therapies harness the regenerative power of exosomes—small biological vesicles naturally released by cells—to promote rapid tissue healing and regulate immune responses. Based on over two decades of pioneering research at Mayo Clinic and advanced biomanufacturing techniques developed by RION, our proprietary exosome technology represents a significant breakthrough in the treatment of chronic wounds and inflammatory skin diseases.
INTENT’s lead therapeutic candidate, PEP Biologic™ (Purified Exosome Product), is a topical biologic that delivers hundreds of billions of regenerative exosomes directly to the site of injury or inflammation. With proven effectiveness in clinical studies, PEP Biologic™ offers a unique solution for conditions currently underserved by traditional therapies, including: biomanufacturing techniques developed by RION, our proprietary exosome technology represents a significant breakthrough in the treatment of chronic wounds and inflammatory skin diseases.
Advanced Tissue Regeneration
Diabetic Foot Ulcers
there is an amputation caused
by a Diabetic Foot Ulcer, ~200k
amputation per year.
Chronic Radiation Ulcers
occur in ~95% of patients that
undergo radiotherapy
treatment.
Pressure Ulcers
hospital stays per year
Surgical Wounds
wound dehiscence
Venous Leg Ulcers
in amputations
No Option Wounds
failed all standards of care and
pose a life-threatening disease
or loss of limb
Diabetic Foot Ulcers
US…there is an
amputation caused by a Diabetic Foot Ulcer, ~200k
amputation per year.
Chronic Radiation Ulcers
injuries occur in ~95% of
patients that undergo
radiotherapy treatment.
Pressure Ulcers
hospital stays per year
Surgical Wounds
rate in wound dehiscence
Venous Leg Ulcers
amputations
No Option Wounds
failed all standards of care
and pose a life-threatening
disease or loss of limb
Autoimmune Dermatology
Atopic Dermatitis
15–30% of children and 2–10%
of adults in developed nations.
Cutaneous Graft vs Host Disease
disease occurs in 40–60% of
patients after allogeneic stem
cell transplantation, often
presenting as rash, sclerosis, or
lichenoid changes.
Alopecia Areata
2% of the global population
over a lifetime and is
characterized by autoimmune-
mediated, non-scarring
hair loss.
Psoriasis
covered with thick, silvery-
white scales surrounded by
smaller red lesions, typically
seen on the arm or elbow.
Seborrheic dermatitis
general population and
presents as a chronic, relapsing
inflammatory skin condition
most commonly seen on the
scalp, face, and upper chest.
Vitiligo
white patches with complete
loss of pigment on a tan to
brown background, commonly
affecting the upper arm.
Atopic Dermatitis
up to 15–30% of children
and 2–10% of adults
in developed nations.
Cutaneous Graft vs
Host Disease
disease occurs in 40–60% of
patients after allogeneic stem
cell transplantation, often
presenting as rash, sclerosis,
or lichenoid changes.
Alopecia Areata
2% of the global population
over a lifetime and
is characterized by
autoimmune-mediated, non
-scarring hair loss.
Psoriasis
skin covered with thick,
silvery-white scales surrounded by smaller red
lesions, typically seen on the
arm or elbow.
Seborrheic dermatitis
the general population and
presents as a chronic,
relapsing inflammatory skin
condition most commonly
seen on the scalp, face, and
upper chest.
Vitiligo
demarcated white patches
with complete loss of pigment
on a tan to brown
background, commonly
affecting the upper arm.

LEADERSHIP
Our leadership team combines decades of industry expertise from leading pharmaceutical and biotechnology companies, supported by renowned scientific and clinical advisors from Mayo Clinic, ensuring strategic direction and rigorous scientific standards in all we do.
Our headquarters in Rochester, Minnesota, host a leadership team with decades of experience from top pharmaceutical and biotechnology companies—guided by esteemed scientific and clinical advisors from Mayo Clinic—to ensure strategic direction and uphold the highest scientific standards in all we do.
Stay updated on our latest clinical advancements, partnerships, and company milestones.